Program Description: The treatment landscape of spinal muscular atrophy (SMA) is changing rapidly. Improved understanding of the molecular basis of SMA, disease pathogenesis, and natural history has yielded significant progress toward the development of novel therapeutic strategies for SMA and the approval of the first treatment for SMA. Keeping pace with these advances can be challenging, and can result in treatment variability and limited ability to support and educate families and caregivers. This activity will be developed with both clinicians and families of children with SMA in mind. For clinicians, topics for discussion include consensus recommendations on the diagnosis and management of SMA, integrating novel therapies in practice, and communicating effectively with families of patients.